Gabapentin for the treatment of menopausal hot flashes

Butt, Debra A.; Lock, Michael; Lewis, Jacqueline; Ross, Sue; Moineddin, Rahim

doi:10.1097/gme.0b013e3180dca175

Cited by 106 publications

(72 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a clinical experiment, Butt et al [11] showed that 300 mg gabapentin three times per day (i.e. 900 mg/day) for 4 weeks significantly reduced the frequency of hot flashes.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women

Rahmanian

Mohseni

Ghorbani

2015

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…In a clinical experiment, Butt et al [11] showed that 300 mg gabapentin three times per day (i.e. 900 mg/day) for 4 weeks significantly reduced the frequency of hot flashes.…”

Section: Discussionmentioning

confidence: 98%

“…Gabapentin is an antiseizure medication that reduces VMS [10,11]. Fluoxetine has also been reported to reduce the symptoms of hot flashes when used for treatment of depression [12].…”

Section: Introductionmentioning

confidence: 99%

A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women

Rahmanian

Mohseni

Ghorbani

2015

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…Advantages include no significant drug interactions, associated sexual dysfunction, or withdrawal symptoms. Disadvantages include dizziness, unsteadiness, and drowsiness in up to 20% of patients 46 . Clonidine can be helpful in patients with mildmoderate hot flushes.…”

Section: Treatment Updates: Care Of the Breast Cancer Survivormentioning

confidence: 99%

Update in New Medications for Primary Care

Smetana

Sillman²

2009

J GEN INTERN MED

View full text Add to dashboard Cite

E ach year, many new drugs find their way into medical practice. Clinicians must determine which are suitable for primary care practice based on comparative efficacy, safety, and cost. Only a fraction of newly approved drugs each year are novel and relevant for primary care. Most new drugs each year are "me too" drugs within existing categories that have marginally differing properties when compared to currently available drugs. To illustrate this point we searched the FDA database for original new drug approvals, including new molecular entities and new biologics, for 2008 1 . We identified 51 new drug approvals. Twenty-six were significant new dosage forms, 10 were significant new biologicals, 10 were used primarily by specialists, 5 were new diagnostic agents (such as radiologic contrast media), and the remaining 6 were relevant for primary care. All six were "me too" drugs. Not a single new drug in 2008 was novel and relevant. Therefore, we elected a different approach this year and identified drugs in the pipeline that are novel, have the potential to be relevant for primary care, and have generated substantial interest in the medical community. To develop a list of candidate drugs, we queried clinical pharmacists that consult for our institutional pharmacy and therapeutics committees, performed an internet search of lay media reports, and reviewed the following journals from

show abstract

“…La dosis recomendada para el tratamiento de los sofocos es de 900 mg/día (54) . Dentro de los efectos adversos, aproximadamente al 20% de las pacientes refieren somnolencia, mareos y cierta anhedonia; aparecen luego de la primera semana de tratamiento y se resuelven espontáneamente luego de la cuarta semana de uso (55) .…”

Section: La Sociedad Internacional De Menopausia (Ims)unclassified

Tratamiento de los síntomas vasomotores en pacientes con cáncer de mama. Revisión narrativa

Susana

Marina

Nardo

et al. 2018

Rev peru ginecol obstet.

View full text Add to dashboard Cite

Rev Peru Ginecol Obstet. 2018;64(1) 69 RESUMENLas mujeres con antecedentes de cáncer de mama suelen experimentar síntomas vasomotores más severos y frecuentes que la población general. Numerosos trabajos han demostrado que los síntomas vasomotores (SVM) son los efectos adversos más frecuentes de la terapia adyuvante, y que hasta 20% de las pacientes con cáncer de mama considera discontinuar el tratamiento debido a estos síntomas, a pesar de su beneficio en la reducción de la recurrencia. Mientras que la terapia sustitutiva hormonal (THM) es usada regularmente en mujeres sanas para tratamiento de los SVM, está contraindicada en pacientes con antecedente de cáncer de mama. Existen muy pocos datos clínicos sobre las intervenciones no farmacológicas, y el papel de las terapias alternativas y complementarias sigue siendo controvertido. La revisión de la literatura da cuenta de que estos agentes farmacológicos, los inhibidores de la recaptación de serotonina-norepinefrina (IRNSs), los inhibidores selectivos de la recaptación de serotonina (IRSs), los antihipertensivos y los anticonvulsivos, disminuyen la intensidad y frecuencia de los SVM, demostrando una mejoría clínicamente significativa. Sin embargo, algunos IRSSs e IRSNs son potentes inhibidores del citocromo P450 2D6 (CYP 2D6), lo que impacta en la concentración de endoxifeno, debiendo ser evitados en pacientes tratadas con tamoxifeno. Son una opción el citalopram y la venlafaxina, si bien su consecuencia sobre la recurrencia y supervivencia del cáncer de mama es controvertida. La eficacia en el tratamiento de los SVM con antidepresivos es menor que con estrógenos y hay pocas publicaciones comparando ambos tratamientos. Faltan datos sobre el lapso de la indicación. Dos fármacos antiepilépticos también han demostrado efectividad, la gabapentina y la pregabalina. Algunas investigaciones comparativas están en curso, y habrá que esperar sus resultados para individualizar cuál es el óptimo en el manejo de los síntomas menopáusicos en mujeres que han padecido cáncer de mama. Palabras clave. Cáncer de mama, Síntomas vasomotores, Antihipertensivos, Antidepresivos, Antiepilépticos. ABSTRACTWomen with a history of breast cancer tend to have more severe and frequent vasomotor symptoms than the general population. Numerous studies have shown that vasomotor symptoms (VMS) are the most frequent adverse event of adjuvant therapy, and that up to 20% of breast cancer patients consider discontinuing treatment because of these symptoms, despite their benefit in the reduction of recurrence. While hormone replacement therapy (HRT) is regularly used in healthy women to treat VMS, it is contraindicated in patients with history of breast cancer. There are few clinical data on non-pharmacological interventions, and the role of alternative and complementary therapies remains controversial. The review of the literature reveals that these pharmacological agents, serotonin-norepinephrine reuptake inhibitors (SSRIs), selective serotonin reuptake inhibitors (IRSs), antihypertensives and antic...

show abstract

Gabapentin for the treatment of menopausal hot flashes

Abstract: Gabapentin at 900 mg/day is an effective and well-tolerated treatment for hot flashes.

Cited by 106 publications

References 32 publications

A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women

A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women

Update in New Medications for Primary Care

Tratamiento de los síntomas vasomotores en pacientes con cáncer de mama. Revisión narrativa

Contact Info

Product

Resources

About